September 5th, 2013
Rosiglitazone Revisited
Richard G. Bach, MD and John Ryan, MD
Richard G. Bach discusses his study group’s observational analysis of data from the BARI 2D trial regarding outcomes associated with rosiglitazone.
NEJM Journal Watch — Recent Cardiology Articles- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension
- Preventive PCI of Vulnerable Plaques Linked to Fewer Cardiac Events
- News from the ACC Scientific Session 2024